BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27453784)

  • 1. Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report.
    Lewen M; Gresh R; Queenan M; Paessler M; Pillai V; Hexner E; Frank D; Bagg A; Aplenc R; Caywood E; Wertheim G
    Biomark Res; 2016; 4():14. PubMed ID: 27453784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
    Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
    Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
    Wang W; Cortes JE; Lin P; Beaty MW; Ai D; Amin HM; McDonnell TJ; Ok CY; Kantarjian HM; Medeiros LJ; Hu S
    Blood; 2015 Oct; 126(14):1699-706. PubMed ID: 26243778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
    Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
    Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors.
    Theil KS; Cotta CV
    Cancer Genet; 2014 May; 207(5):171-6. PubMed ID: 25027637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
    Johansson B; Fioretos T; Mitelman F
    Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
    Pan J; Xue Y; Qiu H; Chen S; Zhang J; Wu Y; Shen J; Wang Y
    Cancer Genet Cytogenet; 2010 Dec; 203(2):333-40. PubMed ID: 21156255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
    Wang W; Tang G; Cortes JE; Liu H; Ai D; Yin CC; Li S; Khoury JD; Bueso-Ramos C; Medeiros LJ; Hu S
    J Hematol Oncol; 2015 Apr; 8():32. PubMed ID: 25888368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a myeloid leukaemia cell line (Kasumi-4) with t(9;22;11)(q34;q11;q13), inv(3)(q21q26) and the EVI1 gene activation from a patient with chronic myelogenous leukaemia in blast crisis.
    Asou H; Eguchi M; Suzukawa K; Morishita K; Tanaka K; Date M; Hamamoto K; Kamada N
    Br J Haematol; 1996 Apr; 93(1):68-74. PubMed ID: 8611478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
    Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
    Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and pathologic characterization of AML with double Inv(3)(q21q26.2).
    Hodge JC; Bosler D; Rubinstein L; Sadri N; Shetty S
    Cancer Genet; 2019 Jan; 230():28-36. PubMed ID: 30503564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.
    Imataki O; Ishida T; Kubo H; Uemura M; Nanya Y; Kawakami K; Ogawa S; Kadowaki N
    Case Rep Oncol; 2020; 13(1):449-455. PubMed ID: 32399015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythroleukemic blast crisis of chronic myeloid leukemia.].
    Chung HJ; Chi HS; Seo EJ; Jang S; Park CJ; Lee KH
    Korean J Lab Med; 2006 Aug; 26(4):255-62. PubMed ID: 18156735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia chromosome-positive acute leukemia: morphologic and clinical correlations.
    Helenglass G; Testa JR; Schiffer CA
    Am J Hematol; 1987 Jul; 25(3):311-24. PubMed ID: 3474891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report.
    Al-Khallaf H; Alali H; Alkhatti A
    Oncol Lett; 2018 Nov; 16(5):6691-6696. PubMed ID: 30405810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
    Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
    Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.